Best Sectors to Watch in November 2026: IT, Banking, Auto, Pharma, or Power?
Last Updated: 18th November 2026 - 03:06 pm
A rising Nifty 50 does not mean every sector is moving in the same direction. The more revealing question in November 2026 is where investors are willing to pay for improving profits, and where a share-price recovery has run ahead of the numbers. The distinction has become especially important after a volatile October. Information technology stocks rebounded sharply, while automobiles and power struggled during that month. Pharmaceuticals stayed relatively resilient, and banks entered November without an especially strong October performance. The first half of November has since reordered that picture.
The earnings season gives this rotation some substance. Banks have reported better lending trends and manageable asset quality, carmakers are testing whether festive volumes can protect margins, IT exporters must show that large deals translate into revenue, drugmakers face different domestic and US market dynamics, and utilities are balancing capacity expansion with funding costs. Rather than declare a permanent winner, this analysis separates the current market leaders from industries where the investment case still needs confirmation.
Banking: November’s Strongest Momentum Needs Earnings Support
Banking sector provides the clearest example of how quickly leadership can change. The Nifty Bank advanced only 0.10% in October, yet financial-sector indices were up roughly 11.5–13.5% in November by 16 November, placing lenders at the centre of the market recovery. The move has a fundamental backdrop. ICICI Bank reported Q2 FY27 net interest income of ₹25,339 crore, up 17.7% year on year, and profit after tax of ₹14,843 crore, up 20.1%. Its net non-performing asset ratio stood at 0.30%. State Bank of India reported quarterly net profit of ₹23,038 crore, up 14.28%, alongside 17.84% growth in advances and a domestic net interest margin of 3.11%. These figures suggest that credit demand and asset quality are offering support beyond the price action.
However, rising bank prices are not proof that every lender has the same earnings trajectory. ICICI Bank’s reported net interest margin eased to 4.18% from 4.36% in the preceding quarter, while SBI’s deposit growth of 12.27% trailed advance growth. Competition for deposits, loan repricing and any fresh provisioning can change the outlook quickly. SBI’s reported Q2 profit also included a ₹7,288 crore one-time gain from an SBI Funds Management stake sale, making recurring profits important to assess. At the end of October, Nifty Bank traded at 12.23 times earnings and 1.65 times book value, but neither ratio is sufficient to establish cheapness without examining return on equity, credit costs and balance-sheet quality. The next test is whether sector outperformance broadens beyond a few heavyweight banks without a deterioration in funding costs.
Auto: Festive Demand Is Strong, but Can Margins Keep Up?
Automobiles sector began November with a measurable demand catalyst. Maruti Suzuki reported 2,76,120 vehicle sales in October 2026, its highest monthly total, while Mahindra & Mahindra reported a 25% year-on-year increase in both consolidated Q2 revenue and profit after tax, to ₹57,553 crore and ₹4,588 crore, respectively. These developments help explain why the auto index gained around 8.5% during the first half of November, reversing much of its October weakness. The opportunity is not confined to one vehicle category: passenger vehicles, sports utility vehicles, two-wheelers, tractors and commercial vehicles are moving at different speeds, offering investors several ways to assess consumer and business demand.
The challenge is separating retail demand from wholesale dispatches to dealers. Festive stocking can lift reported monthly volumes without guaranteeing equally strong sales afterwards. Auto makers also face pressure from steel, aluminium, tyres, logistics and foreign exchange, while electric vehicle investment can raise capital expenditure before revenues mature. Nifty Auto’s 29.06 times P/E at the end of October was well above Nifty Bank’s, implying that earnings delivery matters greatly after the rally. Watch November registrations, dealership inventory, discounts, product mix, and operating margins. A durable shift in relative strength would be more convincing if it extends beyond the largest manufacturers to suppliers without weakening the sector’s profitability.
IT: A Sharp October Rebound Still Needs Revenue Confirmation
Information technology sector produced the most dramatic October reversal among these five sectors. Nifty IT rose 18.06% during the month, far ahead of the Nifty 50’s 1.95% gain, but a rally from depressed prices should not be mistaken for a new earnings cycle. Tata Consultancy Services reported Q2 FY27 revenue of ₹73,188 crore, with constant-currency growth of 0.5% sequentially. Infosys disclosed quarterly revenue of US$5.145 billion, constant-currency growth of 1.2% sequentially, and large-deal total contract value of US$5.2 billion. Nevertheless, Infosys revised its FY27 constant-currency revenue growth guidance to 1–2%, highlighting that demand remains uneven despite deal activity and excitement around artificial intelligence.
The sector’s apparent valuation reset also deserves scrutiny. Nifty IT’s month-end October P/E was 19.98 times, close to the broad market’s 19.30 times, but a lower multiple than historical levels does not automatically signal value if earnings expectations are falling. Investors should ask whether AI projects are generating incremental billable work or replacing traditional services, whether discretionary spending has restarted in the US and Europe, and whether order wins become visible revenue without margin dilution. An improvement in both the sector’s relative-strength ratio against the Nifty 50 and several quarters of organic constant-currency growth would be stronger confirmation than a short covering-led rebound. Until then, IT remains a selective recovery watch rather than a uniformly improving sector.
Pharma: Structural Resilience Comes With a Valuation Premium
Pharmaceuticals sector offer a different profile: their earnings drivers are less closely linked to domestic lending or festive consumption, although currency fluctuations, regulation and drug pricing still matter. Nifty Pharma gained 2.60% in October and delivered a 23.05% return over the preceding year, according to the NSE’s month-end dashboard. Sun Pharmaceutical reported Q2 FY27 consolidated sales of ₹16,100 crore, up 11.8%, with Indian formulations growing 17.3%. Innovative medicines accounted for 21.1% of sales. Cipla reported Q2 global revenue of about ₹7,404 crore, with sequential revenue growth of 4%, reflecting the different growth patterns within the sector. Investors should distinguish domestic branded formulations, US generics, specialty drugs and contract manufacturing rather than treat pharma as a single business model.
Valuation is the immediate constraint. Nifty Pharma’s 42.68 times P/E at the end of October was the highest among the five indices examined, leaving less room for missed launches or disappointing earnings. Even Sun Pharma’s report illustrates the importance of profit quality: adjusted quarterly net profit was ₹3,162 crore, while reported net profit was about ₹1,989 crore. Its US formulations sales declined 8.2% in dollar terms, although India sales grew strongly. The next signals include regulatory approvals, US price erosion, research costs, specialty launches, and domestic prescription growth. Pharma can remain a useful earnings diversifier, but an attractive industry is not automatically an attractively priced index.
Power: Capacity Expansion Is Real, but Returns Must Follow
Power sector where the long-term opportunity and the near-term share-price performance diverge most clearly. Nifty Power declined 2.29% in October, even as power demand, network investment, renewable generation and battery storage continued to attract corporate spending. Tata Power reported Q2 FY27 revenue of ₹19,886 crore, up 26% year on year, and profit after tax of ₹1,652 crore, up 33%; its EBITDA grew a more modest 5%, indicating that revenue growth and operating profitability are not identical. JSW Energy reported quarterly EBITDA growth of 23% and profit after tax growth of 38%, with installed capacity exceeding 15 GW. These are tangible operating milestones, rather than purely thematic statements about the energy transition.
Investors must still separate regulated utilities, thermal generators, transmission companies and renewable developers. Their capital intensity, contracted tariffs, leverage, fuel exposure and cash-flow timing differ substantially. For example, commissioning new wind, solar or storage assets does not instantly eliminate debt-service costs, and an announced project pipeline is not the same as commissioned capacity. At 18.00 times earnings and 2.27 times book value on 31 October, the Nifty Power index appeared less expensive than pharma or auto on an index P/E basis, although its lower multiple also reflects a different mix of businesses and risks. The important November watchpoints are operating cash flow, commissioning schedules, receivables, financing costs and evidence that incremental capital earns an adequate return.
How to Read Sector Rotation Without Chasing It
Relative strength should be measured against a consistent benchmark, not inferred from a single headline. One practical approach is to divide each sector index by the Nifty 50 and track the ratio over four, eight and twelve weeks. A rising ratio means that sector is outperforming the market; a falling ratio indicates relative weakness, even if the index itself is rising. Breadth adds another test. A rally carried by many stocks holding above their 50-day and 200-day moving averages is more convincing than a move supported by only one or two large constituents. Price strength should ideally coincide with improving earnings expectations and reasonable valuations, not merely expand the P/E multiple.
The five sectors can therefore be divided into different watchlist roles. Banking has the strongest confirmed November market leadership, while autos have a powerful volume and earnings catalyst but must prove that festive demand is sustainable. Pharma offers differentiated earnings with an expensive index valuation; power has an investment and commissioning cycle that still needs stronger cash-flow translation; and IT needs further evidence that its sharp recovery is supported by improving demand.
Valuation Matters More After a Fast Rally
A sector comparison is meaningful only when the underlying businesses are comparable. Banks are often evaluated using price-to-book value alongside return on equity, net interest margins, and asset quality. Software and pharmaceutical companies require attention to earnings durability, free cash flow, research spending and growth expectations. Automakers are sensitive to product cycles and input costs, while power companies require careful analysis of capital employed, regulated returns and leverage. Index P/E figures are useful reference points, but sector earnings composition and the influence of exceptional items can distort simple comparisons.
Conclusion
November’s data favour banking as the clearest market leader, with auto stocks close behind on stronger festive sales and selected company results. Yet leadership can reverse as quickly as it emerges. IT’s October recovery remains a test of revenue conversion, pharma pairs resilient business models with demanding valuations, and power combines meaningful investment opportunities with capital and execution risks. Investors should watch whether improving share prices are matched by better earnings, broad sector participation, and healthy cash flows. The purpose of this sector watchlist is to identify where evidence is strongest and where uncertainty remains, rather than to treat any industry as a one-way trade.
- Flat ₹20 Brokerage
- Next-gen Trading
- Advanced Charting
- Actionable Ideas
Trending on 5paisa
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.